Boston Scientific (BSX) Q2 2025 Earnings
How Did BSX Stock React to Q2 2025 Earnings?
S&P 500 over the same 30 days: +1.75%.
Did BSX Beat Earnings? Q2 2025 Results
Yes. Boston Scientific reported Q2 2025 earnings of $0.75 a share on Jul 23, 2025, beating the $0.73 consensus estimate by 2.7%. Revenue was $5.1B against a $4.9B estimate.
Boston Scientific delivered a standout second quarter, posting adjusted EPS of $0.75 against a consensus estimate of $0.73, a beat of 3.42%, while revenue of $5.06 billion topped the $4.89 billion estimate by 3.39% and grew 22.8% year over year. The primary engine behind the quarter was the Cardiovascular segment, which surged 26.8% on a reported basis, driven by Cardiology growth of 29.3% and bolstered by FDA approval to expand the FARAPULSE PFA System labeling to include persistent atrial fibrillation, a key regulatory catalyst that reinforced the company's position in cardiac rhythm management. MedSurg contributed meaningfully as well, with Urology alone advancing 28.9%. Geographically, U.S. growth of 30.7% led all regions. With momentum firmly in hand, Boston Scientific raised its full-year 2025 outlook to 18 to 19 percent reported growth and adjusted EPS of $2.95 to $2.99, while guiding Q3 adjusted EPS to $0.70 to $0.72, signaling continued confidence in the durability of its growth trajectory.
- Exceptional Cardiovascular segment growth of 26.8%, driven by Cardiology (29.3%) and Peripheral Interventions (18.3%)
- U.S. sales growth of 30.7% year-over-year
- Urology business grew 28.9% on a reported basis
- Organic net sales growth of 17.4%, significantly exceeding guidance of 13 to 15 percent
- Margin expansion alongside investment prioritization for future growth
“This was another excellent quarter — marked by exceptional top-line performance — that delivered margin expansion and prioritized investment for future growth.”
Boston Scientific CEO, on the earnings call
What Was Boston Scientific's Outlook in Q2 2025?
For full year 2025, Boston Scientific estimates net sales growth of approximately 18 to 19 percent on a reported basis and 14 to 15 percent on an organic basis. Full year GAAP EPS is estimated at $1.89 to $1.93, with adjusted EPS of $2.95 to $2.99. For Q3 2025, the company estimates net sales growth of approximately 17 to 19 percent on a reported basis and 12 to 14 percent on an organic basis, with GAAP EPS of $0.44 to $0.46 and adjusted EPS of $0.70 to $0.72.
BSX YoY Financials
| Metric | Q2 2025 | Q2 2024 | Year over year |
|---|---|---|---|
| Revenue | $5.1B | $4.1B | +22.8% |
| Gross Profit | $3.4B | $2.6B | +32.5% |
| Operating Income | $819.0M | $747.0M | +9.6% |
| Net Income | $797.0M | $324.0M | +146.0% |
BSX Revenue by Segment
BSX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.